<DOC>
	<DOCNO>NCT00311610</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , liposomal SN-38 , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase II trial study well liposomal SN-38 work treat patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Liposomal SN-38 Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine objective response rate follow treatment SN-38 liposome second-line treatment patient metastatic colorectal cancer . Secondary - Determine toxicity profile drug patient . - Determine proportion patient treated drug experience grade 3 great toxicity . - Determine progression-free survival overall survival patient treated drug . OUTLINE : This multicenter study . Patients receive SN-38 liposome IV 90 minute day 1 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 3 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically determine metastatic colorectal cancer* Primary lesion confirm endoscopically , surgically , radiologically NOTE : * Patients history colorectal cancer treat surgical resection develop radiological clinical evidence metastatic cancer require separate histological cytological confirmation metastatic disease , unless 5 year primary surgery development metastatic disease OR primary cancer stage I Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan Nonmeasurable lesion include follow : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion UGT1A1*1 homozygous UGT1A1*28 heterozygous genotype status Patients homozygous UGT1A1*28 genotype eligible Received least 1 prior regimen oxaliplatin metastatic disease Recurrent disease follow prior adjuvant therapy allow PATIENT CHARACTERISTICS : ECOG performance status 01 Granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine normal Bilirubin normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception duration 3 month completion study treatment No known Gilbert 's disease chronic liver disease No colonic small bowel disorder ( e.g. , inflammatory bowel disease , Crohn 's disease , ulcerative colitis ) predispose patient uncontrolled diarrhea ( i.e. , &gt; 3 watery soft stool daily baseline patient without colostomy ileostomy ) PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy No prior irinotecan Prior pelvic radiotherapy allow long measurable lesion outside irradiated field No concurrent palliative radiotherapy No concurrent chemotherapy No concurrent steroid except give adrenal failure , hormone nondiseaserelated condition ( e.g. , insulin diabetes ) , intermittent dexamethasone antiemetic prevention infusion reaction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>